S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:LEGN

Legend Biotech - LEGN Stock Forecast, Price & News

$41.01
-0.08 (-0.19%)
(As of 10/5/2022 05:11 PM ET)
Add
Compare
Today's Range
$39.93
$41.31
50-Day Range
$38.35
$50.02
52-Week Range
$30.75
$58.00
Volume
516,972 shs
Average Volume
718,327 shs
Market Capitalization
$6.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.80

Legend Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.9% Upside
$66.80 Price Target
Short Interest
Bearish
3.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.19mentions of Legend Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.31) to ($2.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

940th out of 1,072 stocks

Pharmaceutical Preparations Industry

465th out of 534 stocks

LEGN stock logo

About Legend Biotech (NASDAQ:LEGN) Stock

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

LEGN Stock News Headlines

LEGN Legend Biotech Corporation
Oversold Conditions For Legend Biotech (LEGN)
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
See More Headlines
Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

LEGN Company Calendar

Last Earnings
11/16/2021
Today
10/05/2022
Next Earnings (Estimated)
11/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LEGN
Fax
N/A
Employees
1,071
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$66.80
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$53.00
Forecasted Upside/Downside
+62.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-386,210,000.00
Net Margins
-295.68%
Pretax Margin
-296.22%

Debt

Sales & Book Value

Annual Sales
$89.79 million
Book Value
$3.06 per share

Miscellaneous

Free Float
164,059,000
Market Cap
$6.73 billion
Optionable
Not Optionable
Beta
-0.39

Key Executives

  • Dr. Ying Huang Ph.D. (Age 49)
    CEO & Director
  • Ms. Lori A. Macomber CPA
    Chief Financial Officer
  • Joanne Choi
    Sr. Mang. of Investor Relations
  • Mr. Marc Harrison
    VP & Gen. Counsel
  • Deborah Wong
    Exec. Director of Strategic Marketing & Corp. Communications
  • Dr. Meeta Chatterjee Ph.D. (Age 67)
    Sr. VP of Global Bus. Devel.
  • Ms. Liz Gosen
    Sr. VP of Global Technical Operations
  • Dr. Guowei Fang Ph.D.
    Sr. VP & Global Head of Research and Early Devel.
  • Surabhi Verma
    Mang. of Investor Relations & Corp. Communications
  • Dr. Lida Pacaud M.D.
    VP of Clinical Devel.













LEGN Stock - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LEGN shares.
View LEGN analyst ratings
or view top-rated stocks.

What is Legend Biotech's stock price forecast for 2022?

5 equities research analysts have issued 12 month price targets for Legend Biotech's shares. Their LEGN share price forecasts range from $53.00 to $77.00. On average, they anticipate the company's stock price to reach $66.80 in the next year. This suggests a possible upside of 62.6% from the stock's current price.
View analysts price targets for LEGN
or view top-rated stocks among Wall Street analysts.

How have LEGN shares performed in 2022?

Legend Biotech's stock was trading at $46.61 at the beginning of the year. Since then, LEGN shares have decreased by 11.8% and is now trading at $41.09.
View the best growth stocks for 2022 here
.

When is Legend Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 15th 2022.
View our LEGN earnings forecast
.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) announced its quarterly earnings data on Tuesday, November, 16th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.08. The company had revenue of $16.88 million for the quarter, compared to analysts' expectations of $12.50 million. Legend Biotech had a negative trailing twelve-month return on equity of 109.44% and a negative net margin of 295.68%.

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?

(LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the NASDAQ under the ticker symbol "LEGN."

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Legend Biotech's stock price today?

One share of LEGN stock can currently be purchased for approximately $41.09.

How much money does Legend Biotech make?

Legend Biotech (NASDAQ:LEGN) has a market capitalization of $6.74 billion and generates $89.79 million in revenue each year. The company earns $-386,210,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How many employees does Legend Biotech have?

The company employs 1,071 workers across the globe.

How can I contact Legend Biotech?

Legend Biotech's mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The official website for the company is www.legendbiotech.com. The company can be reached via phone at 732-317-5050 or via email at investor@legendbiotech.com.

This page (NASDAQ:LEGN) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.